
The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.
Platinum-Resistant Advanced Ovarian Cancer
Case: A 70-Year-Old Woman Presenting With Advanced Ovarian Cancer
H & P:
Imaging
Biopsy and labs:
Treatment
Follow up:






